filmov
tv
Dr. Fakhri on Ibrutinib-Containing Regimens in CLL
Показать описание
Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the trials that led to ibrutinib (Imbruvica)-containing regimens becoming the standard of care for chronic lymphocytic leukemia (CLL) over traditionally used chemotherapy options.